Anti-inflammatory effects of triptolide improve left ventricular function in a rat model of diabetic cardiomyopathy

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Wen, He Ling ^a,b   Liang, Zhong Shu ^a   Zhang, Rui ^c   Yang, Kan ^a  

^a THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

^b SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c Seventh People's Hospital   (China)

Author keywords

Diabetic cardiomyopathy; Inflammation; NF B; Triptolide

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CREATINE KINASE MB; CREATININE; GLUCOSE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; MESSENGER RNA; STREPTOZOCIN; TRANSCRIPTION FACTOR RELA; TRIPTOLIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CREATININE BLOOD LEVEL; DIABETIC CARDIOMYOPATHY; DOSE RESPONSE; DRUG MEGADOSE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HEART CONTRACTION; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART WEIGHT; INFLAMMATION; LOW DRUG DOSE; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TREATMENT DURATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; DITERPENES; EPOXY COMPOUNDS; MALE; PHENANTHRENES; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR FUNCTION, LEFT;

EID: 84875311323     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-50     Document Type: Article

References (41)

1. Falcao-Pires I, Leite-Moreira AF. Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev 2012, 17:325-344. 10.1007/s10741-011-9257-z, 21626163.
2. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006, 444:860-867. 10.1038/nature05485, 17167474.
3. Stratmann B, Tschoepe D. The diabetic heart: sweet, fatty and stressed. Expert Rev Cardiovasc Ther 2011, 9:1093-1096. 10.1586/erc.11.109, 21932950.
4. Ku PM, Chen LJ, Liang JR, Cheng KC, Li YX, Cheng JT. Molecular role of GATA binding protein 4 (GATA-4) in hyperglycemia-induced reduction of cardiac contractility. Cardiovasc Diabetol 2011, 10:57. 10.1186/1475-2840-10-57, 3141394, 21702924.
5. Lorenzo O, Picatoste B, Ares-Carrasco S, Ramírez E, Egido J, Tunon J. Potential role of nuclear factor κB in diabetic cardiomyopathy. Mediators Inflamm 2011, vol. 2011(Article ID 652097):9.
6. Teixeira-Lemos E, Nunes S, Teixeira F, Reis F. Regular physical exercise training assists in preventing type 2 diabetes development: focus on its antioxidant and anti-inflammatory properties. Cardiovasc Diabetol 2011, 10:12. 10.1186/1475-2840-10-12, 3041659, 21276212.
7. Liu Q. Triptolide and its expanding multiple pharmacological functions. Int Immunopharmacol 2011, 11:377-383. 10.1016/j.intimp.2011.01.012, 21255694.
8. Wong KF, Yuan Y, Luk JM. Tripterygium wilfordii bioactive compounds as anticancer and anti-inflammatory agents. Clin Exp Pharmacol Physiol 2012, 39:311-320. 10.1111/j.1440-1681.2011.05586.x, 21834865.
9. Tao X, Cush JJ, Garret M, Lipsky PE. A phase I study of ethyl acetate extract of the chinese antirheumatic herb Tripterygium wilfordii hook F in rheumatoid arthritis. J Rheumatol 2001, 28:2160-2167.
10. Tao X, Younger J, Fan FZ, Wang B, Lipsky PE. Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 2002, 46:1735-1743. 10.1002/art.10411, 12124856.
11. Cibere J, Deng Z, Lin Y, Ou R, He Y, Wang Z, Thorne A, Lehman AJ, Tsang IK, Esdaile JM. A randomized double blind, placebo controlled trial of topical Tripterygium wilfordii in rheumatoid arthritis: reanalysis using logistic regression analysis. J Rheumatol 2003, 30:465-467.
12. Li R, Takazawa K, Suzuki H, Hariya A, Yamamoto T, Matsushita S, Hirose H, Amano A. Synergistic effect of triptolide and tacrolimus on rat cardiac allotransplantation. Jpn Heart J 2004, 45:657-665. 10.1536/jhj.45.657, 15353876.
13. Liu Y, Chen Y, Liu FQ, Lamb JR, Tam PK. Combined treatment with triptolide and rapamycin prolongs graft survival in a mouse model of cardiac transplantation. Transpl Int 2008, 21:483-494. 10.1111/j.1432-2277.2007.00630.x, 18266776.
14. Gao Q, Shen W, Qin W, Zheng C, Zhang M, Zeng C, Wang S, Wang J, Zhu X, Liu Z. Treatment of db/db diabetic mice with triptolide: a novel therapy for diabetic nephropathy. Nephrol Dial Transplant 2010, 25:3539-3547. 10.1093/ndt/gfq245, 20483955.
15. Van Linthout S, Spillmann F, Riad A, Trimpert C, Lievens J, Meloni M, Escher F, Filenberg E, Demir O, Li J, Shakibaei M, Schimke I, Staudt A, Felix SB, Schultheiss HP, De Geest B, Tschope C. Human apolipoprotein A-I gene transfer reduces the development of experimental diabetic cardiomyopathy. Circulation 2008, 117:1563-1573. 10.1161/CIRCULATIONAHA.107.710830, 18332268.
16. Ares-Carrasco S, Picatoste B, Benito-Martin A, Zubiri I, Sanz AB, Sanchez-Nino MD, Ortiz A, Egido J, Tunon J, Lorenzo O. Myocardial fibrosis and apoptosis, but not inflammation, are present in long-term xperimental diabetes. Am J Physiol Heart Circ Physiol 2009, 297:H2109-2019. 10.1152/ajpheart.00157.2009, 19820199.
17. Sun D, Shen M, Li J, Li W, Zhang Y, Zhao L, Zhang Z, Yuan Y, Wang H, Cao F. Cardioprotective effects of tanshinone IIA pretreatment via kinin B2 receptor-Akt-GSK-3b dependent pathway in experimental diabetic cardiomyopathy. Cardiovasc Diabetol 2011, 10:4. 10.1186/1475-2840-10-4, 3033797, 21232147.
18. Rajesh M, Mukhopadhyay P, Batkai S, Patel V, Saito K, Matsumoto S, Kashiwaya Y, Horvath B, Mukhopadhyay B, Becker L, Hasko G, Liaudet L, Wink DA, Veves A, Mechoulam R, Pacher P. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol 2010, 56:2115-2125. 10.1016/j.jacc.2010.07.033, 3026637, 21144973.
19. Snell-Bergeon JK, West NA, Mayer-Davis EJ, Liese AD, Marcovina SM, D'Agostino RB, Hamman RF, Dabelea D. Inflammatory markers are increased in youth with type 1 diabetes: the SEARCH Case-control study. J Clin Endocrinol Metab 2010, 95:2868-2876. 10.1210/jc.2009-1993, 2902077, 20371668.
20. Westermann D, Van Linthout S, Dhayat S, Dhayat N, Escher F, Bücker-Gartner C, Spillmann F, Noutsias M, Riad A, Schultheiss HP, Tschope C. Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy. Diabetes 2007, 56:1834-1841. 10.2337/db06-1662, 17473225.
21. Westermann D, Van Linthout S, Dhayat S, Dhayat N, Schmidt A, Noutsias M, Song XY, Spillmann F, Riad A, Schultheiss HP, Tschope C. Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol 2007, 102:500-507. 10.1007/s00395-007-0673-0, 17909696.
22. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004, 94:1543-1553. 10.1161/01.RES.0000130526.20854.fa, 15217919.
23. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979, 241:2035-2038. 10.1001/jama.1979.03290450033020, 430798.
24. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F,. ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. ADVANCE Collaborative Group.
25. Castagno D, Baird-Gunning J, Jhund PS, Biondi-Zoccai G, MacDonald MR, Petrie MC, Gaita F, McMurray JJ. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. Am Heart J 2011, 162:938-948. e2, 10.1016/j.ahj.2011.07.030, 22093212.
26. Vaz Perez A, Doehner W, von Haehling S, Schmidt H, Zimmermann AV, Volk HD, Anker SD, Rauchhaus M. The relationship between tumor necrosis factor-α, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure. Int J Cardiol 2010, 141:39-43. 10.1016/j.ijcard.2008.11.146, 19155075.
27. Miettinen KH, Lassus J, Harjola VP, Siirila-Waris K, Melin J, Punnonen KR, Nieminen MS, Laakso M, Peuhkurinen KJ. Prognostic role of pro- and anti-inflammatory cytokines and their polymorphisms in acute decompensated heart failure. Eur J Heart Fail 2008, 10:396-403. 10.1016/j.ejheart.2008.02.008, 18353715.
28. Sun M, Chen M, Dawood F, Zurawska U, Li JY, Parker T, Kassiri Z, Kirshenbaum LA, Arnold M, Khokha R, Liu PP. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 2007, 115:1398-1407. 10.1161/CIRCULATIONAHA.106.643585, 17353445.
29. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004, 109:1594-1602. 10.1161/01.CIR.0000124490.27666.B2, 15023878.
30. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT,. Anti-TNF Therapy Against Congestive Heart Failure Investigators Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003, 107:3133-3140. 10.1161/01.CIR.0000077913.60364.D2, 12796126, Anti-TNF Therapy Against Congestive Heart Failure Investigators.
31. Gong Y, Xue B, Jiao J, Jing L, Wang X. Triptolide inhibits COX-2 expression and PGE2 release by suppressing the activity of NF-kappaB and JNK in LPS-treated microglia. J Neurochem 2008, 107:779-788. 10.1111/j.1471-4159.2008.05653.x, 18761708.
32. Kizelsztein P, Komarnytsky S, Raskin I. Oral administration of triptolide ameliorates the clinical signs of experimental autoimmune encephalomyelitis (EAE) by induction of HSP70 and stabilization of NF-kappaB/IkappaBalpha transcriptional complex. J Neuroimmunol 2009, 217:28-37. 10.1016/j.jneuroim.2009.08.017, 19796825.
33. Wu Y, Cui J, Bao X, Chan S, Young DO, Liu D, Shen P. Triptolide attenuates oxidative stress, NF-kappaB activation and multiple cytokine gene expression in murine peritoneal macrophage. Int J Mol Med 2006, 17:141-150.
34. Lu Y, Bao X, Sun T, Xu J, Zheng W, Shen P. Triptolide attenuate the oxidative stress induced by LPS/D-GalN in mice. J Cell Biochem 2012, 113:1022-1033. 10.1002/jcb.23434, 22065336.
35. Li CJ, Lv L, Li H, Yu DM. Cardiac fibrosis and dysfunction in experimental diabetic cardiomyopathy are ameliorated by alpha-lipoic acid. Cardiovasc Diabetol 2012, 11:73. 10.1186/1475-2840-11-73, 3472273, 22713251.
36. Lee JE, Yi CO, Jeon BT, Shin HJ, Kim SK, Jung TS, Choi JY, Roh GS. Alpha-lipoic acid attenuates cardiac fibrosis in Otsuka Long-Evans Tokushima Fatty rats. Cardiovasc Diabetol 2012, 11:111. 10.1186/1475-2840-11-111, 3558371, 22992429.
37. Matta R, Wang X, Ge H, Ray W, Nelin LD, Liu Y. Triptolide induces anti-inflammatory cellular responses. Am J Transl Res 2009, 1:267-282. 2776323, 19956437.
38. Wold LE, Ren J. Streptozotocin directly impairs cardiac contractile function in isolated ventricular myocytes via a p38 map kinase-dependent oxidative stress mechanism. Biochem Biophys Res Commun 2004, 318:1066-1071. 10.1016/j.bbrc.2004.04.138, 15147982.
39. Katovich MJ, Hanley K, Strubbe G, Wright BE. Effects of streptozotocin-induced diabetes and insulin treatment on blood pressure in the male rat. Proc Soc Exp Biol Med 1995, 208:300-306.
40. Zhang X, Chen C. A new insight of mechanisms, diagnosis and treatment of diabetic cardiomyopathy. Endocrine 2012, 41:398-409. 10.1007/s12020-012-9623-1, 22322947.
41. Kumar S, Singh R, Vasudeva N, Sharma S. Acute and chronic animal models for the evaluation of anti-diabetic agents. Cardiovasc Diabetol 2012, 11:9. 10.1186/1475-2840-11-9, 3286385, 22257465.